#### SUPPLEMENTAL MATERIALS

## **Cohort description**

Data came from the Avon Longitudinal Study of Parents and Children (ALSPAC), a prospective, longitudinal birth cohort of children born to mothers who were living in the county of Avon England (120 miles west of London) with estimated delivery dates between April 1991 and December 1992 ALSPAC was designed to identify the determinants of health across the lifespan, with an emphasis on genetic and environmental factors. The initial number of pregnancies enrolled is 14,541 (for these at least one questionnaire has been returned or a "Children in Focus" clinic had been attended by 19/07/99). Of these initial pregnancies, there was a total of 14,676 fetuses, resulting in 14,062 live births and 13,988 children who were alive at 1 year of age. When the oldest children were approximately 7 years old, an attempt was made to bolster the initial sample with eligible cases who had failed to join the study originally, resulting in an additional 913 children being enrolled. As such, the total sample size for analyses using any data collected after the age of seven is therefore 15,454 pregnancies, resulting in 15,589 fetuses. Of these 14,901 were alive at 1 year of age. The ALSPAC website contains details of all the data that is available through a fully searchable data dictionary and variable search tool: www.bristol.ac.uk/alspac/researchers/our-data/. Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committee. Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time.

#### Genotyping, quality control, and imputation

We performed standard quality control measures to exclude youths on the basis of gender mismatch, minimal or excessive heterozygosity, individual genotyping call rates < 97%, insufficient sample replication (IBD<0.8), cryptic relatedness (IBD>0.1), and non-European ancestry (assessed using multidimensional scaling analysis and compared to HapMap II, release 22). For the current analyses, we further excluded 21 youths who self-reported as non-whites. We excluded genotyped SNPs based on the following criteria: minor allele frequency <1%; missing rate >5%; and significant deviation from Hardy-Weinberg Equilibrium (p<1e-7). We conducted imputation using Impute V2.2.2 against the 1000 genomes reference panel (Phase 1, version 3), with 2,186 reference haplotypes including non-Europeans (Abecasis et al., 2012; Marchini, Howie, Myers, McVean, & Donnelly, 2007).

Confirmatory factor analysis of the growth mixture modeling with structured residuals

As noted in the main text, we used confirmatory factor analysis to combine information across
all questionnaire items into a single factor score estimate representing the latent cause of their
shared variability, which we interpreted as *depressive* symptoms (Hawrilenko, Masyn, Cerutti, &
Dunn, 2020; Kline, 2015). Preliminary measurement invariance analyses revealed that some
items changed over time due to non-depression-related factors, suggesting scalar non-invariance.

We accounted for this scalar non-invariance by combining items into parcels (meaning, the
averaged subsets of items) with internally consistent patterns of scalar non-invariance; we also
released scalar constraints on the non-invariant waves, allowing the non-invariant parcels to
contribute to factor score information within each wave, but not to changes in factor scores
across waves (Little, Cunningham, Shahar, & Widaman, 2002). Standardized factor loadings
were moderate to strong for items representing emotional difficulties (range: 0.61 to 0.81) and in

the moderate range for peer difficulties (range: 0.39 to 0.55). Full details of the measurement invariance analyses can be found in the technical supplement for Hawrilenko and colleagues, 2020 (*Child Development*).

### Polygenic risk score (PRS) generation and selection

Prior to score construction, we performed additional genomic quality control procedures by removing imputed SNPs with imputation quality metric score <0.8, MAF <1%, call rate <95%, and HWE p<1e-6. SNPs were then pruned for linkage disequilibrium using p-value informed clump-based pruning in PLINK v1.90 (r<sup>2</sup>=0.25 within a 250kb window). We created the PRS in PLINK v.1.07, using methods described by Purcell et al., where the PRS for each youth was the sum of the risk alleles (0, 1, or 2) for each SNP at a given p-value threshold weighted by the logarithm of its odds ratio (OR) for MDD in the PGC GWAS (Purcell et al., 2007). Using Pthe summary statistics from Howard et al., 2019 (PGC-MDD2, UK Biobank, 23andme) as the discovery sample and the ALSPAC cohort as the training sample, we selected independent subsets of SNPs from GWAS summary data at 10 GWAS significance thresholds (p<sub>T</sub>), 0.0001, 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, and 1. We standardized all PRS prior to analysis so that all reported ORs could be interpreted as a one standard deviation increase in the score. As the PRS with p<sub>T</sub><0.1 explained the most phenotypic variance in the analytic sample compared to the other scores (Wald omnibus value = 45.8; Chi-squared p-value < 1e-4; Figure S6), we focused on the results from this 'best model fit' score.

## Modal class assignment in the MAGMA analysis

Modal class assignments were used in the gene-level MAGMA analysis, as to our knowledge, no

existing software tools currently exist to account for measurement error/classification uncertainty inherent to GMM in genome-wide analyses. To this end, participants were assigned to latent classes based on posterior probabilities of their membership in each latent class, calculated from their observed data and the latent class model parameters. Each youth had probabilities summing to 100%, reflecting their probability of assignment to each of the 6 latent classes. To assign a modal class to each individual, we selected the latent class with the highest probability. Using this approach, the average modal class probability (i.e., the highest probability class for each individual) across all individuals was 76% (SD = 18%; Figure S2). With this approach, the number of youths assigned to each trajectory class was estimated as follows: 4,146 minimal symptoms (56.7%), 182 adolescent spike (2.5%), 222 late childhood peak (3%), 440 childhood decrease (6%), 423 high/reversing (5.8%), and 1,895 high/renitent (25.9%). Although modalclass assignment may lead to lower standard errors to or overly-optimistic inferential tests, point estimates remained unbiased (Vermunt, 2017). We also note that modal class proportions are slightly different from the model-estimated proportions reported in Figure 1, as they do not take into account the "second place" and "third place" class assignments for each individual (Hawrilenko et al., 2020).

## Sensitivity analyses of class assignment in the MAGMA analyses

We performed additional analyses in MAGMA using trajectories classes. First, we performed a case/control analysis on individuals in the high/renitent and minimal symptoms class who had a modal class probability equal to or greater than 80%. This threshold resulted in 786 youths in the high/renitent class and 2,258 youths in the minimal symptoms class (Figure S9). Second, we performed an analysis on continuous probabilities for the high/renitent class across all

individuals (0-100%) (Figure S8).

#### **Author contributions**

AAL analyzed the data, compiled the results, and wrote the manuscript. MH performed the analyses in MPlus. MW generated the polygenic risk scores. KC and JC helped with writing and interpretation of findings. YZ helped with data analysis of the ALSPAC cohort. ECD helped write the manuscript and compile the results. All authors provided critical feedback at all stages of the manuscript.

## References

- Abecasis, G. R., Auton, A., Brooks, L. D., DePristo, M. A., Durbin, R. M., Handsaker, R. E., Kang, H. M., et al. (2012). An integrated map of genetic variation from 1,092 human genomes. *Nature*, 491(7422), 56–65.
- Hawrilenko, M., Masyn, K. E., Cerutti, J. K., & Dunn, E. C. (2020). Individual differences in the course of youth depression: The importance of renitence and reversion. *medRxiv*, 19012872.Retrieved from http://medrxiv.org/content/early/2019/11/27/19012872.abstract
- Kline, R. B. (2015). *Principles and Practice of Structural Equation Modeling, Fourth Edition*.

  Methodology in the Social Sciences. Guilford Publications. Retrieved from https://books.google.com/books?id=Q61ECgAAQBAJ
- Little, T. D., Cunningham, W. A., Shahar, G., & Widaman, K. F. (2002). To Parcel or Not to Parcel: Exploring the Question, Weighing the Merits. *Structural Equation Modeling: A Multidisciplinary Journal*, *9*(2), 151–173. Routledge. Retrieved from https://doi.org/10.1207/S15328007SEM0902\_1
- Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007). A new multipoint

- method for genome-wide association studies by imputation of genotypes. *Nat Genet*, *39*(7), 906–913. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17572673
- Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A., Bender, D., Maller, J., et al. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*, 81(3), 559–575. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17701901
- Vermunt, J. K. (2017). Latent Class Modeling with Covariates: Two Improved Three-Step Approaches. *Political Analysis*, *18*(4), 450–469. Cambridge University Press. Retrieved from https://www.cambridge.org/core/article/latent-class-modeling-with-covariates-two-improved-threestep-approaches/7DEF387D6ED4CF0A26A2FA06F9470D02

# SUPPLEMENTAL TABLES

Table S1. Summary of the analytical subsample from the ALSPAC cohort

|                                | Original Sample (N=15445) | Analytic Sample (N=7,308) | Original vs.<br>Analytic |
|--------------------------------|---------------------------|---------------------------|--------------------------|
|                                | n (%)                     | n (%)                     | χ2 p-value               |
| Sex                            |                           |                           |                          |
| Males                          | 7542 (51.3)               | 3707 (50.7)               | 0.151                    |
| Females                        | 7152 (48.7)               | 3601 (49.3)               |                          |
| Race                           |                           |                           |                          |
| Non-white                      | 611 (5.1)                 | 0 (0)                     | < 0.001                  |
| White                          | 11488 (94.9)              | 6639 (100.0)              |                          |
| Age of Mother at Child's Birth |                           |                           |                          |
| Ages 15-19                     | 650 (4.6)                 | 142 (2.0)                 | < 0.001                  |
| Ages 20-35                     | 12363 (88.4)              | 6281 (89.8)               |                          |
| Age 36+                        | 968 (6.9)                 | 575 (8.2)                 |                          |
| Parental Social Class          |                           |                           |                          |
| Professional                   | 1419 (9.6)                | 942 (12.9)                | < 0.001                  |
| Managerial and technical       | 4288 (29.0)               | 2583 (35.3)               |                          |
| Skilled, non-manual            | 2623 (17.8)               | 1456 (19.9)               |                          |
| Skilled, manual                | 909 (6.2)                 | 438 (6.0)                 |                          |
| Semi-skilled, manual           | 270 (1.8)                 | 125 (1.7)                 |                          |
| Unskilled, manual/other        | 5254 (35.6)               | 1764 (24.1)               |                          |
| Number of previous pregnancies |                           |                           |                          |
| 0                              | 5800 (44.7)               | 3045 (44.9)               | < 0.001                  |
| 1                              | 4550 (35.0)               | 2480 (36.6)               |                          |
| 2                              | 1860 (14.3)               | 921 (13.6)                |                          |
| 3+                             | 772 (5.9)                 | 330 (4.9)                 |                          |
| Birth weight (g)               |                           |                           |                          |
| < 3000                         | 3649 (24.8)               | 1572 (21.5)               | < 0.001                  |
| 3000 - 3499                    | 4924 (33.5)               | 2446 (33.5)               |                          |
| 3500 - 3999                    | 4382 (29.8)               | 2338 (32.0)               |                          |
| >= 4000                        | 1735 (11.8)               | 952 (13.0)                |                          |
| Maternal Education             |                           |                           |                          |
| less than O-level              | 3735 (30.0)               | 1575 (23.3)               | < 0.001                  |
| O-level                        | 4303 (34.6)               | 2366 (35.1)               |                          |
| A-level                        | 2795 (22.5)               | 1724 (25.5)               |                          |
| Degree or Above                | 1603 (12.9)               | 1084 (16.1)               |                          |
| Maternal Marital Status        |                           | •                         |                          |
| Never Married                  | 2522 (19.2)               | 950 (13.9)                | < 0.001                  |
|                                |                           |                           |                          |

 Widowed/Divorced/Separated
 787 (6.0)
 364 (5.3)

 Married
 9838 (74.8)
 5529 (80.8)

Table S2. Means, standard deviations, and correlations for study variables

| Variable           | n<br>(% non-<br>missing) | M    | SD   | Min/Max   | 1    | 2    | 3    | 4    | 5    | 6    | 7    |
|--------------------|--------------------------|------|------|-----------|------|------|------|------|------|------|------|
| 1. Dep. 3.9 years  | 6054 (82.8)              | 0.75 | 0.30 | 0.13/1.88 |      |      |      |      |      |      |      |
| 2. Dep. 6.8 years  | 5644 (77.2)              | 0.76 | 0.35 | 0.05/1.99 | 0.79 |      |      |      |      |      |      |
| 3. Dep.8.1 years   | 5414 (74.1)              | 0.83 | 0.36 | 0.07/2.05 | 0.71 | 0.90 |      |      |      |      |      |
| 4. Dep.9.6 years   | 5632 (77.1)              | 0.75 | 0.38 | 0.00/2.00 | 0.63 | 0.83 | 0.87 |      |      |      |      |
| 5. Dep.11.7 years  | 5275 (72.2)              | 0.73 | 0.39 | 0.06/2.17 | 0.54 | 0.75 | 0.78 | 0.83 |      |      |      |
| 6. Dep.13.1 years  | 5099 (69.8)              | 0.73 | 0.40 | 0.04/2.20 | 0.54 | 0.73 | 0.74 | 0.79 | 0.85 |      |      |
| 7. Dep. 16.5 years | 4167 (57.0)              | 0.74 | 0.40 | 0.02/2.24 | 0.51 | 0.65 | 0.69 | 0.68 | 0.72 | 0.77 |      |
| 8. Child PRS       | 7308 (100.0)*            | 0.00 | 1.00 | 4.24/3.48 | 0.06 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 |

*Note*. M = Mean. SD = Standard Deviation. Dep = Depression. PRS = Polygenic Risk Score. Participants were included in the count of non-missing if they had at least one complete parcel of the SDQ or SMFQ. \*Child PRS was non-missing by definition, as all participants with missing PRS were excluded.

Table S3. Growth parameters for the unconditional six-class growth mixture model with structured residuals

Late Minimal Adolescent Childhood Childhood High and High and **Symptoms** Spike Peak Decrease Reversing Renitent Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE) Parameter Means 0.61 (0.008) 0.78 (0.03) 0.68 (0.03) 0.84 (0.05) 0.91 (0.02) Intercept 1.03 (0.03) -0.23(0.04)-0.28(0.19)0.90(0.19)0.09(0.18)0.62 (0.17) 0.68 (0.06) Slope -2.39 (0.48) -0.89(0.23)**Ouadratic** 0.59 (0.12) 1.81 (0.97) -3.30(0.80)-0.22(0.84)Cubic -0.70(0.14)-3.01 (1.20) 4.82 (0.80) 2.45 (0.48) -0.74(1.03)0.39 (0.25) -0.69 (0.16) 0.41 (0.36) -0.06(0.09)**Ouartic** 0.26 (0.05) 1.41 (0.43) -2.01(0.34)Structured Residual 0.43 (0.04) 0.42 (0.17) -0.49(0.05)0.15 (0.09) -0.41 (0.03) 0.87 (0.01) 1.09 (0.01) Area under the curve 0.87 (0.004) 1.27 (0.03) 1.34 (0.02) 1.44 (0.02) 1.61 (0.006) Variances\* Intercept 0.042 (0.002) 0.042 (0.002) 0.042 (0.002) 0.042 (0.002) 0.042 (0.002) 0.042 (0.002) Linear Slope 0.013 (0.001) 0.013 (0.001) 0.013 (0.001) 0.013 (0.001) 0.013 (0.001) 0.013 (0.001)

Latent Class

*Note.* \*Linear time was coded as months divided by 100 and higher order time transformations were based off of that. Variances were constrained equal across latent classes. Quadratic and higher order variances were constrained to zero within each class.

Table S4. Sensitivity analysis examining difference in PRS effects when controlling for mother's PRS score

| Comparison                | , v                     | Child PI<br>(N = 531 | •     | Model Includes Mother PRS Scores (N = 5311) |      |      |             |               | Difference Between<br>Models   |                              |
|---------------------------|-------------------------|----------------------|-------|---|------|------|-------------|---------------|--------------------------------|------------------------------|
|                           |                         | Child Ef             | fects | Child Effe                                  | ects |      | Mother Et   | <u>ffects</u> |                                |                              |
| Reference Category        | Alternative<br>Category | Log<br>Odds          | SE    | Log<br>Odds                                 | SE   |      | Log<br>Odds | SE            | Change in child log odds (raw) | Change in child log odds (%) |
| Minimal Symptoms          | Adolescent Spike        | 0.14                 | 0.11  | 0.13  |      | 0.12 | 0.03        | 0.10          | -0.02                          | -10%                         |
| Minimal                   | Late Childhood          |                      |       |   |      |      |             |               |                                |                              |
| Symptoms                  | Peak                    | 0.21#                | 0.10  | 0.15  | (    | 0.12 | 0.12        | 0.13          | -0.06                          | -30%                         |
| Minimal Symptoms          | Childhood<br>Decrease   | 0.08                 | 0.08  | 0.07  |      | 0.09 | 0.02        | 0.09          | -0.01                          | -14%                         |
| Minimal Symptoms  Minimal | High and                | 0.00                 | 0.08  | 0.07  | •    | 0.09 | 0.02        | 0.09          | -0.01                          | -14/0                        |
| Symptoms                  | Reversing               | 0.22*                | 0.08  | 0.16  |      | 0.10 | 0.12        | 0.08          | -0.06                          | -28%                         |
| Minimal                   | High and                |                      |       |   |      |      |             |               |                                |                              |
| <b>Symptoms</b>           | Renitent                | 0.24*                | 0.05  | 0.16*                                       |      | 0.06 | 0.16        | 0.06          | -0.08                          | -35%                         |
|                           | Late Childhood          |                      |       |   |      |      |             |               |                                |                              |
| Adolescent Spike          | Peak                    | 0.07                 | 0.15  | 0.02  | (    | 0.16 | 0.09        | 0.16          | -0.05                          | -70%                         |
| A 1 1                     | Childhood               | 0.06                 | 0.12  | 0.06  |      | 0.15 | 0.01        | 0.12          | 0.00                           | <i>(</i> 0/                  |
| Adolescent Spike          | Decrease                | -0.06                | 0.13  | -0.06                                       | (    | 0.15 | -0.01       | 0.13          | 0.00                           | -6%                          |
| Adolescent Spike          | High and Reversing      | 0.07                 | 0.13  | 0.03  |      | 0.15 | 0.09        | 0.12          | -0.05                          | -62%                         |
| Adolescent Spike          | High and Renitent       | 0.10                 | 0.12  | 0.03  |      | 0.13 | 0.13        | 0.11          | -0.07                          | -69%                         |
| Late Childhood            | Childhood               | 0.10                 | 0.12  | 0.03  | ·    | 0.13 | 0.13        | 0.11          | 0.07                           | 0770                         |
| Peak                      | Decrease                | -0.13                | 0.12  | -0.08                                       |      | 0.14 | -0.11       | 0.14          | 0.05                           | -39%                         |
| Late Childhood            | High and                |                      |       |   |      |      |             |               |                                |                              |
| Peak                      | Reversing               | 0.01                 | 0.13  | 0.01  | (    | 0.14 | -0.01       | 0.14          | 0.00                           | 0%                           |
| Late Childhood            |                         |                      |       |   |      |      |             |               |                                |                              |
| Peak                      | High and Renitent       | 0.03                 | 0.11  | 0.01  | (    | 0.13 | 0.04        | 0.13          | -0.02                          | -69%                         |
| Childhood                 | High and                | 0.14                 | 0.11  | 0.00  |      | 0.12 | 0.10        | 0.11          | 0.05                           | 2.60/                        |
| Decrease                  | Reversing               | 0.14                 | 0.11  | 0.09  | (    | 0.12 | 0.10        | 0.11          | -0.05                          | -36%                         |

| Childhood          | High and          |       |      |      |      |      |      |       |      |  |
|--------------------|-------------------|-------|------|------|------|------|------|-------|------|--|
| Decrease           | Renitent          | 0.16* | 0.08 | 0.09 | 0.10 | 0.14 | 0.09 | -0.07 | -45% |  |
| High and Reversing | High and Renitent | 0.03  | 0.09 | 0.00 | 0.11 | 0.04 | 0.09 | -0.02 | -96% |  |

*Note.* Comparisons that were statistically significant in the original analysis are bolded for ease of interpretation. Log odds are shown rather than odds ratios because the model is linear in terms of log odds, which facilitates comparisons between parameters in percentage terms. The N is smaller than the N for the original model because 1997 participants with child genetic data did not also have mother genetic data, and they were listwise deleted to facilitate direct comparisons in changes across models. \*FDR < 0.05; \*P < 0.05, but PDR > 0.05.

Table S5. Summary of gene-based hits using MAGMA.

| Gene   | Chr | Start    | Stop     | # of SNPs | $\mathbb{R}^2$ | P-value             | Association |
|--------|-----|----------|----------|-----------|----------------|---------------------|-------------|
| GABRA4 | 4   | 46920917 | 46996424 | 218       | 0.0069         | 6.84e <sup>-5</sup> | HR vs MS    |
| LRR1   | 14  | 50065415 | 50081390 | 43        | 0.0045         | 4.71e <sup>-5</sup> | HR vs MS    |
| SIX5   | 19  | 46268043 | 46272497 | 3         | 0.0029         | 9.16e <sup>-6</sup> | AUC         |
| DMPK   | 19  | 46272975 | 46285815 | 17        | 0.0030         | 4.97e <sup>-5</sup> | AUC         |
| DKK1   | 10  | 54074041 | 54077417 | 5         | 0.0023         | 9.23e <sup>-5</sup> | AUC         |
| SIX5   | 19  | 46268043 | 46272497 | 3         | 0.0033         | 5.56e <sup>-6</sup> | Intercept   |
| DMPK   | 19  | 46272975 | 46285815 | 17        | 0.0042         | 1.05e <sup>-5</sup> | Intercept   |
| SMDT1  | 22  | 42475695 | 42480288 | 6         | 0.0033         | 2.31e <sup>-5</sup> | Intercept   |
| DMWD   | 19  | 46286264 | 46296060 | 17        | 0.0041         | 9.79e <sup>-5</sup> | Intercept   |

<sup>\*</sup>HR = high/renitent class; MS = minimal symptoms class; AUC = cumulative burden of depressive symptoms; intercept = onset of depressive symptoms

| Table S6. Child a | nd mother | characteristics | stratified by | latent class |
|-------------------|-----------|-----------------|---------------|--------------|
|                   |           |                 |               |              |

|                                 | Overall     | Minimal<br>Symptoms | Adolescent<br>Spike | Late<br>Childhood<br>Peak | Childhood<br>Decrease | High and<br>Reversing | High and<br>Renitent | χ2 p-<br>value |
|---------------------------------|-------------|---------------------|---------------------|---------------------------|-----------------------|-----------------------|----------------------|----------------|
| n                               | 7308        | 4146                | 182                 | 222                       | 440                   | 423                   | 1895                 |                |
| Mother's age at birth (%)       |             |                     |                     |                           |                       |                       |                      |                |
| Ages 15-19                      | 142 (2.0)   | 71 (1.8)            | 1 (0.6)             | 4 (1.8)                   | 10 (2.3)              | 7 (1.7)               | 49 (2.7)             | 0.73           |
| Ages 20-35                      | 6281 (89.8) | 3568 (89.9)         | 160 (90.4)          | 194 (89.4)                | 389 (89.4)            | 365 (90.1)            | 1605 (89.5)          |                |
| Age 36+                         | 575 (8.2)   | 332 (8.4)           | 16 (9.0)            | 19 (8.8)                  | 36 (8.3)              | 33 (8.1)              | 139 (7.8)            |                |
| Marital status (%)              |             |                     |                     |                           |                       |                       |                      |                |
| Never Married                   | 950 (13.9)  | 516 (13.3)          | 15 (8.6)            | 18 (8.5)                  | 58 (13.6)             | 59 (14.9)             | 284 (16.3)           | 0.02           |
| Widowed/ Divorced/<br>Separated | 364 (5.3)   | 203 (5.2)           | 7 (4.0)             | 9 (4.2)                   | 19 (4.4)              | 27 (6.8)              | 99 (5.7)             |                |
| Married                         | 5529 (80.8) | 3167 (81.5)         | 152 (87.4)          | 186 (87.3)                | 350 (82.0)            | 310 (78.3)            | 1364 (78.1)          |                |
| Parent SES (%)                  |             |                     |                     |                           |                       |                       |                      |                |
| Professional                    | 942 (12.9)  | 561 (13.5)          | 21 (11.5)           | 33 (14.9)                 | 63 (14.3)             | 61 (14.4)             | 203 (10.7)           | 0.035          |
| Managerial and technical        | 2583 (35.3) | 1456 (35.1)         | 75 (41.2)           | 91 (41.0)                 | 156 (35.5)            | 155 (36.6)            | 650 (34.3)           |                |
| Skilled, non-manual             | 1456 (19.9) | 823 (19.9)          | 47 (25.8)           | 44 (19.8)                 | 91 (20.7)             | 82 (19.4)             | 369 (19.5)           |                |
| Skilled, manual                 | 438 (6.0)   | 245 (5.9)           | 1 (0.5)             | 13 (5.9)                  | 27 (6.1)              | 25 (5.9)              | 127 (6.7)            |                |
| Semi-skilled, manual            | 125 (1.7)   | 69 (1.7)            | 2 (1.1)             | 3 (1.4)                   | 8 (1.8)               | 4 (0.9)               | 39 (2.1)             |                |
| Unskilled, manual/other         | 1764 (24.1) | 992 (23.9)          | 36 (19.8)           | 38 (17.1)                 | 95 (21.6)             | 96 (22.7)             | 507 (26.8)           |                |
| Mother's education (%)          |             |                     |                     |                           |                       |                       |                      |                |
| Less than O-level               | 1575 (23.3) | 873 (22.8)          | 27 (15.4)           | 43 (19.9)                 | 94 (22.0)             | 85 (21.4)             | 453 (26.4)           | 0.01           |
| O-level                         | 2366 (35.1) | 1360 (35.6)         | 63 (36.0)           | 66 (30.6)                 | 147 (34.4)            | 131 (33.0)            | 599 (35.0)           |                |
| A-level                         | 1724 (25.5) | 1000 (26.2)         | 54 (30.9)           | 62 (28.7)                 | 102 (23.9)            | 104 (26.2)            | 402 (23.5)           |                |
| Degree or above                 | 1084 (16.1) | 588 (15.4)          | 31 (17.7)           | 45 (20.8)                 | 84 (19.7)             | 77 (19.4)             | 259 (15.1)           |                |
| Child sex (%)                   |             |                     |                     |                           |                       |                       |                      |                |
| Female                          | 3601 (49.3) | 1976 (47.7)         | 120 (65.9)          | 111 (50.0)                | 188 (42.7)            | 231 (54.6)            | 975 (51.5)           | < 0.001        |
| Male                            | 3707 (50.7) | 4145 (52.3)         | 62 (34.1)           | 111 (50.0)                | 252 (57.3)            | 192 (45.4)            | 920 (48.5)           |                |

| Previous preganancies (%) |             |             |           |            |            |            |            |       |
|---------------------------|-------------|-------------|-----------|------------|------------|------------|------------|-------|
| 0                         | 3045 (44.9) | 1631 (42.5) | 81 (47.1) | 100 (46.7) | 199 (46.8) | 191 (48.6) | 843 (48.7) | 0.006 |
| 1                         | 2480 (36.6) | 1481 (38.6) | 59 (34.3) | 79 (36.9)  | 151 (35.5) | 128 (32.6) | 582 (33.6) |       |
| 2                         | 921 (13.6)  | 538 (14.0)  | 29 (16.9) | 31 (14.5)  | 58 (13.6)  | 50 (12.7)  | 215 (12.4) |       |
| 3+                        | 330 (4.9)   | 191 (5.0)   | 3 (1.7)   | 4 (1.9)    | 17 (4.0)   | 24 (6.1)   | 91 (5.3)   |       |
| Birthweight               |             |             |           |            |            |            |            |       |
| < 3000                    | 1572 (21.5) | 850 (20.5)  | 39 (21.4) | 48 (21.6)  | 78 (17.7)  | 102 (24.1) | 455 (24.0) | 0.063 |
| 3000 - 3499               | 2446 (33.5) | 1382 (33.3) | 61 (33.5) | 76 (34.2)  | 170 (38.6) | 135 (31.9) | 622 (32.8) |       |
| 3500 - 3999               | 2338 (32.0) | 1355 (32.7) | 57 (31.3) | 58 (26.1)  | 142 (32.3) | 127 (30.0) | 599 (31.6) |       |
| >= 4000                   | 952 (13.0)  | 559 (13.5)  | 25 (13.7) | 40 (18.0)  | 50 (11.4)  | 59 (13.9)  | 219 (11.6) |       |

*Note*. Participant characteristics were determined by assigning each individual to their most likely latent class. SES = Socioeconomic status. PRS = Polygenic risk score.

#### SUPPLEMENTAL FIGURES




Figure S1. Flowchart of ALSPAC sample selection. Of the eligible participants after 1 year (14,901), two subsamples were selected: those with genetic data (9,912) and those with at least one measure of depressive symptoms from age 4-16 (11,641). Following quality control measures, the genetic subsample was reduced to 8,082 individuals. The overlap between these two samples was 7,308 individuals, which we defined as the analytical sample for the polygenic risk score (PRS) analyses of depressive symptom trajectories, as well as gene-level associations with depressive symptom onset and cumulative burden using MAGMA. The analytical sample was further subset to 6,041 individuals for the trajectory class-based MAGMA analysis, which focused solely on youths classified as high/renitent or minimal symptoms for the depressive symptom trajectories.






Figure S2. Probability of class assignment for individuals within their assigned latent class.

Each individual was assigned to the trajectory class reflecting their highest probability of assignment across all classes (which ranged from 0-100). Within each class, the probability of highest assignment ranged from 0.3 to 1. The percentage of youths assigned to each trajectory class was estimated as follows: 4,146 minimal symptoms (56.7%), 182 adolescent spike (2.5%), 222 late childhood peak (3%), 440 childhood decrease (6%), 423 high/reversing (5.8%), and 1,895 high/renitent (25.9%).



**Figure S3. The PRS with pT<0.1 was the 'best fit' polygenic risk score.** Using the Wald omnibus test of parameter constraints, we show that the polygenic risk score (PRS) generated with the p-value threshold of p<0.1 (green) explained the most variance in the depression trajectories.



**Figure S4. Polygenic risk scores identified differences in membership to classes of depressive symptom trajectories.** Odds ratios (OR) were calculated to determine the odds of membership of each class versus the referent given a one unit increase in polygenic risk score (PRS). While five contrasts were significant (p<0.05), only four remained significant after multiple test correction at an FDR<0.05 (high/stable vs minimal symptoms; high/stable vs childhood decrease; high/unstable vs minimal symptoms).







Figure S5. Quantile-quantile (QQ) plots of gene-level genome-wide associations show good model fit of the MAGMA analysis. A) The QQ plot of the high/stable (HS) and minimal symptoms (MS) classes of depressive symptoms trajectories showed good model fit, with a slight downward skew. B) The QQ plot of depressive symptom persistence across age 4-16, defined as the area under the curve (AUC) of the trajectory was slightly skewed upward, but showed good model fit. C) The QQ plot of depressive symptom onset, defined by the intercept of the trajectory, was also slightly skewed upward and showed good model fit.



**Figure S6. Depressive symptom developmental features showed nominal gene-level associations. A)** The contrast of high/renitent (HR) and minimal symptoms (MS) classes showed two nominal associations (GABRA4, LRR1). **B)** Depressive symptom cumulative burden (AUC) showed three nominal associations (SIX5, DPMK, DKK1). **C)** Depressive symptom onset (intercept) showed four nominal associations (SIX5, DPKM, SMDT1, DMWD). Genome-wide significance was set at 2.93e-6 (red) and the nominal threshold was set at 1e-4 (blue).



**Figure S7** shows the model-estimated proportion of individuals in each latent class across low (-2 SD) average and high (+2 standard deviation) polygenic risk scores. For example, about 60% of participants with a risk score 2 standard deviations below the average would be expected to be in the Minimal Symptoms class, whereas only 40% of participants with a risk score 2 standard deviations above average would be expected to be in the Minimal Symptoms class.





 Gene
 Chr
 Start
 Stop
 # of SNPs
 R²
 P-value

 SYCP2L
 6
 10887064
 10974542
 220
 0.0072
 9.37e-5

Figure S8. MAGMA analysis of the probability of assignment to the high/renitent class.

MAGMA was performed using all 7,308 individuals and their probability of being assigned to the high/renitent class was used to identify gene-level associations. No genes reached the genome-wide significance threshold (p<2.93e-7; red line in B), but one gene reached the nominal threshold of p<1e4 (blue line in B; results shown in C).





| C)     |     |           |           |           |                |                     |
|--------|-----|-----------|-----------|-----------|----------------|---------------------|
| Gene   | Chr | Start     | Stop      | # of SNPs | R <sup>2</sup> | P-value             |
| CTLA4  | 2   | 204732511 | 204738683 | 5         | 0.0086         | 8.17e <sup>-6</sup> |
| OVOS   | 12  | 9613794   | 9725776   | 14        | 0.0092         | 8.58e <sup>-5</sup> |
| ABHD13 | 13  | 108870763 | 108886603 | 38        | 0.0097         | 4.82e <sup>-5</sup> |

Figure S9. MAGMA analysis of youths in the high/renitent vs minimal symptoms class class. MAGMA was performed using youths in the high/renitent (HR) or minimal symptoms (MS) classes that had 80% probability of class assignment (2258 MS vs 786 HR). No genes reached the genome-wide significance threshold (p<2.93e-7; red line in B), but three genes reached the nominal threshold of p<1e4 (blue line in B; results shown in C).

## Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium

Stefan Herms 35, 47 Giorgio Pistis 27 Naomi R Wray\* 1, 2 Stephan Ripke\* 3, 4, 5 Danielle Posthuma 86, 87 Ian B Hickie 56 Manuel Mattheisen\* 6, 7, 8 Per Hoffmann 35, 47 Jorge A Quiroz 88 Per Ovist 8, 13, 24 Maciei Trzaskowski 1 Georg Homuth 57 John P Rice 89 Enda M Byrne 1 Carsten Horn 58 Abdel Abdellaoui 9 Jouke-Jan Hottenga 9 Brien P. Riley 17 Mark J Adams 10 David M Hougaard 13,18 Margarita Rivera 28, 90 Esben Agerbo 11, 12, 13 David M Howard 10, 28 Saira Saeed Mirza 36 Tracy M Air 14 Marcus Ising 59 Robert Schoevers 91 Till F M Andlauer 15, 16 Rick Jansen 19 Eva C Schulte 92, 93 Silviu-Alin Bacanu 17 Ian Jones 60 Ling Shen 62 Marie Bækvad-Hansen 13, 18 Lisa A Jones 61 Jianxin Shi 94 Aartjan T F Beekman 19 Eric Jorgenson 62 Stanley I Shyn 95 Tim B Bigdeli 17, 20 James A Knowles 63 Engilbert Sigurdsson 96 Elisabeth B Binder 15, 21 Grant C B Sinnamon 97 Isaac S Kohane 64, 65, 66 Julien Bryois 22 Julia Kraft 4 Johannes H Smit 19 Daniel J Smith 98 Henriette N Buttenschøn 13, 23, Warren W. Kretzschmar 67 Zoltán Kutalik 68, 69 Hreinn Stefansson 99 Jonas Bybjerg-Grauholm 13, 18 Yihan Li 67 Stacy Steinberg 99 Fabian Streit 45 Na Cai 25, 26 Penelope A Lind 29 Enrique Castelao 27 Donald J MacIntyre 70, 71 Jana Strohmaier 45 Jane Hvarregaard Christensen 8, Dean F MacKinnon 50 Katherine E Tansey 100 13, 24 Robert M Maier 2 Henning Teismann 101 Toni-Kim Clarke 10 Wolfgang Maier 72 Alexander Teumer 102 Jonathan Marchini 73 Jonathan R I Coleman 28 Wesley Thompson 13, 54, 103, Lucía Colodro-Conde 29 Hamdi Mbarek 9 Baptiste Couvy-Duchesne 2, 30 Patrick McGrath 74 Pippa A Thomson 105 Nick Craddock 31 Peter McGuffin 28 Thorgeir E Thorgeirsson 99 Gregory E Crawford 32, 33 Sarah E Medland 29 Matthew Traylor 106 Gail Davies 34 Divya Mehta 2, 75 Jens Treutlein 45 Ian J Deary 34 Christel M Middeldorp 9, 76, 77 Vassily Trubetskoy 4 Franziska Degenhardt 35 Evelin Mihailov 78 Andrés G Uitterlinden 107 Eske M Derks 29 Yuri Milaneschi 19 Daniel Umbricht 108 Lili Milani 78 Nese Direk 36, 37 Sandra Van der Auwera 109 Conor V Dolan 9 Francis M Mondimore 50 Albert M van Hemert 110 Erin C Dunn 38, 39, 40 Grant W Montgomery 1 Alexander Viktorin 22 Thalia C Eley 28 Sara Mostafavi 79, 80 Peter M Visscher 1, 2 Valentina Escott-Price 41 Niamh Mullins 28 Yunpeng Wang 13, 54, 104 Farnush Farhadi Hassan Kiadeh Matthias Nauck 81, 82 Bradley T. Webb 111 42 Bernard Ng 80 Shantel Marie Weinsheimer 13, Hilary K Finucane 43, 44 Michel G Nivard 9 Jerome C Foo 45 Dale R Nyholt 83 Jürgen Wellmann 101 Andreas J Forstner 35, 46, 47, Paul F O'Reilly 28 Gonneke Willemsen 9 Hogni Oskarsson 84 Stephanie H Witt 45 Michael J Owen 60 Yang Wu 1 Josef Frank 45 Jodie N Painter 29 Hualin S Xi 112 Héléna A Gaspar 28 Jian Yang 2, 113 Michael Gill 49 Carsten Bøcker Pedersen 11, 12, Fernando S Goes 50 Futao Zhang 1 Scott D Gordon 29 Marianne Giørtz Pedersen 11, Volker Arolt 114 Jakob Grove 8, 13, 24, 51 12, 13 Bernhard T Baune 115, 116, 117 Lynsey S Hall 10, 52 Klaus Berger 101 Roseann E Peterson 17, 85 Christine Søholm Hansen 13, 18 Erik Pettersson 22 Dorret I Boomsma 9

Wouter J Peyrot 19

Thomas F Hansen 53, 54, 55

Sven Cichon 35, 47, 118, 119

Udo Dannlowski 114

EJC de Geus 9, 120

J Raymond DePaulo 50

Enrico Domenici 121

Katharina Domschke 122, 123

Tõnu Esko 5, 78

Hans J Grabe 109

Steven P Hamilton 124

Caroline Hayward 125

Andrew C Heath 89

Kenneth S Kendler 17

Stefan Kloiber 59, 126, 127

Glyn Lewis 128

Qingqin S Li 129

Susanne Lucae 59

Pamela AF Madden 89

Patrik K Magnusson 22

Nicholas G Martin 29

Andrew M McIntosh 10, 34

Andres Metspalu 78, 130

Ole Mors 13, 131

Preben Bo Mortensen 11, 12,

13, 24

Bertram Müller-Myhsok 15,

132, 133

Merete Nordentoft 13, 134

Markus M Nöthen 35

Michael C O'Donovan 60

Sara A Paciga 135

Nancy L Pedersen 22

Brenda WJH Penninx 19

Roy H Perlis 38, 136

David J Porteous 105

James B Potash 137

Martin Preisig 27

Marcella Rietschel 45

Catherine Schaefer 62

Thomas G Schulze 45, 93, 138,

139, 140

Jordan W Smoller 38, 39, 40

Kari Stefansson 99, 141

Henning Tiemeier 36, 142, 143

Rudolf Uher 144

Henry Völzke 102

Myrna M Weissman 74, 145

Thomas Werge 13, 54, 146

Cathryn M Lewis\* 28, 147

Douglas F Levinson\* 148

Gerome Breen\* 28, 149

Anders D Børglum\* 8, 13, 24

Patrick F Sullivan\* 22, 150,

151,

- 1, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, AU
- 2, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, AU
- 3, Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, US
- 4, Department of Psychiatry and Psychotherapy, Universitätsmedizin Berlin Campus Charité Mitte, Berlin, DE
- 5, Medical and Population Genetics, Broad Institute, Cambridge, MA, US
- 6, Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wurzburg, Wurzburg, DE
- 7, Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SE
- 8, Department of Biomedicine, Aarhus University, Aarhus, DK
- 9, Dept of Biological Psychology & EMGO+ Institute for Health and Care Research, Vrije Universiteit Amsterdam, Amsterdam, NL
- 10, Division of Psychiatry, University of Edinburgh, Edinburgh, GB
- 11, Centre for Integrated Register-based Research, Aarhus University, Aarhus, DK
- 12, National Centre for Register-Based Research, Aarhus University, Aarhus, DK
- 13, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, DK
- 14, Discipline of Psychiatry, University of Adelaide, Adelaide, SA, AU
- 15, Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, DE
- 16, Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, DE
- 17, Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, US
- 18, Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, DK
- 19, Department of Psychiatry, Vrije Universiteit Medical Center and GGZ inGeest, Amsterdam, NL
- 20, Virginia Institute for Psychiatric and Behavior Genetics, Richmond, VA, US
- 21, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, US
- 22, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, SE
- 23, Department of Clinical Medicine, Translational Neuropsychiatry Unit, Aarhus University, Aarhus, DK
- 24, iSEQ, Centre for Integrative Sequencing, Aarhus University, Aarhus, DK
- 25, Human Genetics, Wellcome Trust Sanger Institute, Cambridge, GB
- 26, Statistical genomics and systems genetics, European Bioinformatics Institute (EMBL-EBI), Cambridge, GB
- 27, Department of Psychiatry, Lausanne University Hospital and University of Lausanne, CH
- 28, Social, Genetic and Developmental Psychiatry Centre, King's College London, London, GB
- 29, Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, AU
- 30, Centre for Advanced Imaging, The University of Queensland, Brisbane, QLD, AU
- 31, Psychological Medicine, Cardiff University, Cardiff, GB
- 32, Center for Genomic and Computational Biology, Duke University, Durham, NC, US
- 33, Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, NC, US
- 34, Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, GB
- 35, Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, DE
- 36, Epidemiology, Erasmus MC, Rotterdam, Zuid-Holland, NL
- 37, Psychiatry, Dokuz Eylul University School Of Medicine, Izmir, TR
- 38, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, US
- 39, Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Massachusetts General Hospital, Boston, MA, US
- 40, Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, US
- 41, Neuroscience and Mental Health, Cardiff University, Cardiff, GB
- 42, Bioinformatics, University of British Columbia, Vancouver, BC, CA
- 43, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, US
- 44. Department of Mathematics, Massachusetts Institute of Technology, Cambridge, MA, US
- 45, Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty
- Mannheim, Heidelberg University, Mannheim, Baden-Württemberg, DE
- 46. Department of Psychiatry (UPK), University of Basel, Basel, CH
- 47, Department of Biomedicine, University of Basel, Basel, CH
- 48, Centre for Human Genetics, University of Marburg, Marburg, DE
- 49, Department of Psychiatry, Trinity College Dublin, Dublin, IE
- 50, Psychiatry & Behavioral Sciences, Johns Hopkins University, Baltimore, MD, US
- 51, Bioinformatics Research Centre, Aarhus University, Aarhus, DK
- 52, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, GB

- 53, Danish Headache Centre, Department of Neurology, Rigshospitalet, Glostrup, DK
- 54, Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Mental Health Services Capital Region of Denmark, Copenhagen, DK
- 55, iPSYCH, The Lundbeck Foundation Initiative for Psychiatric Research, Copenhagen, DK
- 56, Brain and Mind Centre, University of Sydney, Sydney, NSW, AU
- 57, Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine and Ernst Moritz Arndt University Greifswald, Greifswald, Mecklenburg-Vorpommern, DE
- 58, Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH
- 59, Max Planck Institute of Psychiatry, Munich, DE
- 60, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, GB
- 61, Department of Psychological Medicine, University of Worcester, Worcester, GB
- 62, Division of Research, Kaiser Permanente Northern California, Oakland, CA, US
- 63, Psychiatry & The Behavioral Sciences, University of Southern California, Los Angeles, CA, US
- 64, Department of Biomedical Informatics, Harvard Medical School, Boston, MA, US
- 65, Department of Medicine, Brigham and Women's Hospital, Boston, MA, US
- 66, Informatics Program, Boston Children's Hospital, Boston, MA, US
- 67, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, GB
- 68, Institute of Social and Preventive Medicine (IUMSP), University Hospital of Lausanne, Lausanne, VD, CH
- 69, Swiss Institute of Bioinformatics, Lausanne, VD, CH
- 70, Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, GB
- 71, Mental Health, NHS 24, Glasgow, GB
- 72, Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, DE
- 73, Statistics, University of Oxford, Oxford, GB
- 74, Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, US
- 75, School of Psychology and Counseling, Queensland University of Technology, Brisbane, QLD, AU
- 76, Child and Youth Mental Health Service, Children's Health Queensland Hospital and Health Service, South Brisbane, QLD, AU
- 77, Child Health Research Centre, University of Queensland, Brisbane, QLD, AU
- 78, Estonian Genome Center, University of Tartu, Tartu, EE
- 79, Medical Genetics, University of British Columbia, Vancouver, BC, CA
- 80, Statistics, University of British Columbia, Vancouver, BC, CA
- 81, DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, University Medicine, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, DE
- 82, Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, DE
- 83, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, AU
- 84, Humus, Reykjavik, IS
- 85, Virginia Institute for Psychiatric & Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, US
- 86, Clinical Genetics, Vrije Universiteit Medical Center, Amsterdam, NL
- 87, Complex Trait Genetics, Vrije Universiteit Amsterdam, Amsterdam, NL
- 88, Solid Biosciences, Boston, MA, US
- 89, Department of Psychiatry, Washington University in Saint Louis School of Medicine, Saint Louis, MO, US
- 90, Department of Biochemistry and Molecular Biology II, Institute of Neurosciences, Biomedical Research Centre (CIBM), University of Granada, Granada, ES
- 91, Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, NL
- 92, Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University Munich, Munich, DE
- 93, Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, Ludwig Maximilian University Munich, Munich, DE
- 94, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, US
- 95, Behavioral Health Services, Kaiser Permanente Washington, Seattle, WA, US
- 96, Faculty of Medicine, Department of Psychiatry, University of Iceland, Reykjavik, IS
- 97, School of Medicine and Dentistry, James Cook University, Townsville, QLD, AU
- 98, Institute of Health and Wellbeing, University of Glasgow, Glasgow, GB

- 99, deCODE Genetics / Amgen, Reykjavik, IS
- 100, College of Biomedical and Life Sciences, Cardiff University, Cardiff, GB
- 101, Institute of Epidemiology and Social Medicine, University of Münster, Münster, Nordrhein-Westfalen, DE
- 102, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, DE
- 103, Department of Psychiatry, University of California, San Diego, San Diego, CA, US
- 104, KG Jebsen Centre for Psychosis Research, Norway Division of Mental Health and Addiction, Oslo University Hospital, Oslo, NO
- 105, Medical Genetics Section, CGEM, IGMM, University of Edinburgh, Edinburgh, GB
- 106, Clinical Neurosciences, University of Cambridge, Cambridge, GB
- 107, Internal Medicine, Erasmus MC, Rotterdam, Zuid-Holland, NL
- 108, Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases Discovery & Translational Medicine Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH
- 109, Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, DE
- 110, Department of Psychiatry, Leiden University Medical Center, Leiden, NL
- 111, Virginia Institute for Psychiatric & Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, US
- 112, Computational Sciences Center of Emphasis, Pfizer Global Research and Development, Cambridge, MA, US
- 113, Institute for Molecular Bioscience; Queensland Brain Institute, The University of Queensland, Brisbane, QLD, AU
- 114, Department of Psychiatry, University of Münster, Münster, Nordrhein-Westfalen, DE
- 115, Department of Psychiatry, University of Münster, Münster, DE
- 116, Department of Psychiatry, Melbourne Medical School, University of Melbourne, Melbourne, AU
- 117, Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, AU
- 118, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, CH
- 119, Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, DE
- 120, Amsterdam Public Health Institute, Vrije Universiteit Medical Center, Amsterdam, NL
- 121, Centre for Integrative Biology, Università degli Studi di Trento, Trento, Trentino-Alto Adige, IT
- 122, Department of Psychiatry and Psychotherapy, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, DE
- 123, Center for NeuroModulation, Faculty of Medicine, University of Freiburg, Freiburg, DE
- 124, Psychiatry, Kaiser Permanente Northern California, San Francisco, CA, US
- 125, Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, GB
- 126, Department of Psychiatry, University of Toronto, Toronto, ON, CA
- 127, Centre for Addiction and Mental Health, Toronto, ON, CA
- 128, Division of Psychiatry, University College London, London, GB
- 129, Neuroscience Therapeutic Area, Janssen Research and Development, LLC, Titusville, NJ, US
- 130, Institute of Molecular and Cell Biology, University of Tartu, Tartu, EE
- 131, Psychosis Research Unit, Aarhus University Hospital, Risskov, Aarhus, DK
- 132, Munich Cluster for Systems Neurology (SyNergy), Munich, DE
- 133, University of Liverpool, Liverpool, GB
- 134, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, DK
- 135, Human Genetics and Computational Biomedicine, Pfizer Global Research and Development, Groton, CT, US
- 136, Psychiatry, Harvard Medical School, Boston, MA, US
- 137, Psychiatry, University of Iowa, Iowa City, IA, US
- 138, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, US
- 139, Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Goettingen, Niedersachsen. DE
- 140, Human Genetics Branch, NIMH Division of Intramural Research Programs, Bethesda, MD, US
- 141, Faculty of Medicine, University of Iceland, Reykjavik, IS
- 142, Child and Adolescent Psychiatry, Erasmus MC, Rotterdam, Zuid-Holland, NL
- 143, Psychiatry, Erasmus MC, Rotterdam, Zuid-Holland, NL
- 144, Psychiatry, Dalhousie University, Halifax, NS, CA
- 145, Division of Epidemiology, New York State Psychiatric Institute, New York, NY, US

- 146, Department of Clinical Medicine, University of Copenhagen, Copenhagen, DK
- 147, Department of Medical & Molecular Genetics, King's College London, London, GB 148, Psychiatry & Behavioral Sciences, Stanford University, Stanford, CA, US
- 149, NIHR Maudsley Biomedical Research Centre, King's College London, London, GB
- 150, Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, US
- 151, Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, US